Abstract
The level of 6-keto-PGF1α and thromboxane B2 (TXB2) in plasma was determined with radioimmunoassay in 58 normal subjects and 92 patients with various cancers (including lung, hepatic, gastric, esophageal and pancreatic carcinoma). The results showed that 6-keto-PGF1α in plasma was 10.21±2.75 Pg/ml, and TXB2 146.03±37.31 Pg/ml in normal individuals, the ratio of 6-keto-PGF1α to TXB2 was 0.07; while in cancer patients 6-keto-PGFIα was 27.5±16.9 Pg/ml and TXB2 315.4±173.4 Pg/ml, the ratio of 6-keto-PGFIα to TXB2 was 0.08. The values of 6-keto-PGFIα and TXB2 in plasma of cancer patients were 2.69 folds and 2.16 folds higher than that of the two groups, respectively. The difference between the two groups was statistically significant (P<0.01). It indicates that, the synthesis and release of PGI2 and TXA2 of cancer tissues increases greatly as compared to the normals.
The study also revealed that the size of tumor, metastasis and histological classification had no obvious relation to PGs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bennett A, Stamford IF, Berstock DA, et al. Breast cancer, prostaglandins and patient survival. Br J Cancer 1989; 59:268.
Laekeman GM, Vergote IB, Keersmaekers GH, et al. Prostacyclin and thromboxane in benign and malignant breast tumors. Br J Cancer 1986; 54:431.
Vergote IB, Laekeman GM, Keersmaekers GH, et al. Prostaglandin F2α in benign and malignant breast tumors. Br J Cancer 1985; 51:827.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tan, Y., Wang, B., Lin, F. et al. Relation of malignant tumor to prostacyclin and thromboxane. Chinese Journal of Cancer Research 7, 75–78 (1995). https://doi.org/10.1007/BF02954713
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02954713